During the last session, Dyne Therapeutics Inc (NASDAQ:DYN)’s traded shares were 0.84 million, with the beta value of the company hitting 1.10. At the end of the trading day, the stock’s price was $25.73, reflecting an intraday gain of 0.47% or $0.12. The 52-week high for the DYN share is $47.45, that puts it down -84.42 from that peak though still a striking 58.03% gain since the share price plummeted to a 52-week low of $10.80. The company’s market capitalization is $2.62B, and the average intraday trading volume over the past 10 days was 0.72 million shares, and the average trade volume was 1.02 million shares over the past three months.
Dyne Therapeutics Inc (DYN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. DYN has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Dyne Therapeutics Inc (DYN) registered a 0.47% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.47% in intraday trading to $25.73, hitting a weekly high. The stock’s 5-day price performance is -12.78%, and it has moved by -24.61% in 30 days. Based on these gigs, the overall price performance for the year is 127.30%. The short interest in Dyne Therapeutics Inc (NASDAQ:DYN) is 10.35 million shares and it means that shorts have 9.33 day(s) to cover.
The consensus price target of analysts on Wall Street is $52.5, which implies an increase of 50.99% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $42 and $55 respectively. As a result, DYN is trading at a discount of -113.76% off the target high and -63.23% off the low.
Dyne Therapeutics Inc (DYN) estimates and forecasts
Statistics show that Dyne Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Dyne Therapeutics Inc (DYN) shares have gone down -22.20% during the last six months, with a year-to-date growth rate less than the industry average at 12.66% against 16.40.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -106.26%. While earnings are projected to return 12.22% in 2024.
DYN Dividends
Dyne Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Dyne Therapeutics Inc insiders own 0.77% of total outstanding shares while institutional holders control 112.64%, with the float percentage being 113.52%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the largest shareholder of the company, while 292.0 institutions own stock in it. As of 2024-06-30, the company held over 8.02 million shares (or 9.8961% of all shares), a total value of $283.03 million in shares.
The next largest institutional holding, with 7.85 million shares, is of FCPM III SERVICES B.V.’s that is approximately 9.6804% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $276.86 million.
